Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2010
03/31/2010CN101687038A Novel formulation
03/31/2010CN101687037A Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
03/31/2010CN101687036A CHK1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
03/31/2010CN101687035A Novel compounds
03/31/2010CN101687034A Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same
03/31/2010CN101687033A Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
03/31/2010CN101687032A Antagonist antibodies against ephb3
03/31/2010CN101687031A Compositions and methods for treating ocular diseases and conditions
03/31/2010CN101687030A Improved methods for producing yeast-based vaccines
03/31/2010CN101687029A An hbv vaccine and a process of preparing the same
03/31/2010CN101687028A 疫苗 Vaccine
03/31/2010CN101687027A immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
03/31/2010CN101687026A mutated e. coli heat-labile enterotoxin
03/31/2010CN101687025A Haemophilus influenzae type B
03/31/2010CN101687024A trypanosoma antigens, vaccine compositions, and related methods
03/31/2010CN101687023A Diagnostic method
03/31/2010CN101687022A prame derived peptides and immunogenic compositions comprising these
03/31/2010CN101687021A uses of monoclonal antibody 8h9
03/31/2010CN101687020A multivalent entrain-and-amplify immunotherapeutics for carcinoma
03/31/2010CN101687008A Therapeutic agent and detection reagent for arteriosclerotic disease which targets for thallusin
03/31/2010CN101686971A Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
03/31/2010CN101686690A Compositions and methods useful for modulating immunity, enhancing vaccine efficacy, decreasing morbidity associated with chronic fhv-1 infections, and preventing or treating conjunctivitis
03/31/2010CN101684499A Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
03/31/2010CN101684158A Binding domain-immunoglobulin fusion proteins
03/31/2010CN101684157A anti-ox40l antibodies
03/31/2010CN101684156A Human TNF alpha monoclonal antibody, PEGylation nanoparticle and application thereof
03/31/2010CN101684155A Nucleotide and protein sequences of nogo genes and methods based thereon
03/31/2010CN101684148A Novel surface protein of neisseria meningitidis
03/31/2010CN101684147A moraxella catarrhalis proteins
03/31/2010CN101684146A Novel hcv non-structural polypeptide
03/31/2010CN101683525A Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
03/31/2010CN101683524A Method for preparing bacterial ghost by combination of antibacterial peptide and ultrahigh pressure and application thereof
03/31/2010CN101683523A Preparation method of prostatic cancer specific DC cell vaccine which is insensitive to TGF-belta
03/31/2010CN101683520A Methods for treating tweak-related conditions
03/31/2010CN101683354A Liver damage relevant drug target and application thereof
03/31/2010CN101683326A Super concentrated natural allicin tablets with quick-acting antibiosis, anti-inflammation and antivirus and preparation method thereof
03/30/2010US7687615 PAV regions for encapsidation and E1 transcriptional control
03/30/2010US7687611 Assay for the separation and quantification of hemagglutinin antigens
03/30/2010US7687607 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLS)
03/30/2010US7687606 Fully human monoclonal antibodies that inhibit neovascularization of solid tumors; assaying for MCP-1; cancer diagnosis; may be conjugated to a chemotherapeutic agent such as taxol, doxorubicin, cis-platinum, and 5-fluorouracil.
03/30/2010US7687605 Antibody comprising a human heavy chain framework sequence, three heavy chain hypervariable region sequences and three light chain hypervariable region sequences; modulating biological activity of integrins containing the beta7 subunit
03/30/2010US7687459 serine protease inhibitors; interferons
03/30/2010US7687455 comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy
03/30/2010US7687240 Process for increasing RSV surface glycoprotein yields using a mutant strain of RSV
03/30/2010US7687074 Prevent adhesion of pathogens; mixture containing fatty acid, or glycerides thereof
03/30/2010US7687063 monoclonal antibodies, hybridomas; immunoglobulins, fab fragments
03/30/2010US7687062 Method for diagnosing colon cancer
03/30/2010US7687061 Method of modulating the activity of functional immune molecules to Her-2
03/30/2010US7687060 Method for the treatment or prophylaxis of tuberculosis
03/30/2010CA2433069C Latent human tuberculosis model, diagnostic antigens, and methods of use
03/30/2010CA2372633C Staphylococcus aureus antigen-containing whole cell vaccine
03/30/2010CA2241604C Mesothelium antigen and methods and kits for targeting it
03/30/2010CA2174652C Nucleotide vector, composition containing such vector and vaccine for immunization against hepatitis
03/30/2010CA2170523C Cloned glutamic acid decarboxylase
03/25/2010WO2010034015A2 Modulating the alternative complement pathway
03/25/2010WO2010033923A2 Genus-wide chlamydial peptide vaccine antigens
03/25/2010WO2010033913A1 Antibodies, analogs and uses thereof
03/25/2010WO2010033884A2 Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
03/25/2010WO2010033866A2 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
03/25/2010WO2010033863A2 Vaccine compositions of m2e, ha0 and bm2 multiple antigenic peptides
03/25/2010WO2010033841A1 Immunotherapy for chronic hepatitis c virus infection
03/25/2010WO2010033798A2 Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
03/25/2010WO2010033736A1 Novel compositons and methods for treating ige-mediated disorders
03/25/2010WO2010033667A2 Wstf regulates the dna damage response of h2a.x via novel tyrosine kinase activity
03/25/2010WO2010033587A2 Methods for treating progressive multiple sclerosis
03/25/2010WO2010033514A1 Methods for reducing viral load of hepatitus c virus in hemodialysis patients
03/25/2010WO2010033507A1 Method of enhancing tgf-beta signalling
03/25/2010WO2010033486A1 Vaccines containing canine parvovirus genetic variants
03/25/2010WO2010033337A1 Rabies virus-based recombinant immunocontraceptive compositions and methods of use
03/25/2010WO2010033279A2 Antibodies with altered binding to fcrn and methods of using same
03/25/2010WO2010033275A2 Orally administerable vaccine for yersinia pestis
03/25/2010WO2010033274A2 Nanoemulsion adjuvants
03/25/2010WO2010032696A1 Diagnosis method and therapeutic method for cancer
03/25/2010WO2010032408A1 Vaccine preparation for neospora caninum infection
03/25/2010WO2010032228A1 Allergoids derived from allergenes
03/25/2010WO2010032220A1 Stable liquid antibody formulation
03/25/2010WO2010032177A1 Methods and compositions for diagnosing and treating a colorectal adenocarcinoma
03/25/2010WO2010032139A1 Bacterial and fungal vaccines for the treatment of asthma
03/25/2010WO2010032138A2 Vaccine adjuvant combinations
03/25/2010WO2010032061A1 Antibodies against sonic hedgehog homolog and uses thereof
03/25/2010WO2010032060A1 Antibodies directed to dll4 and uses thereof
03/25/2010WO2010032059A2 Targeted binding agents directed to cd105 and uses thereof
03/25/2010WO2010031883A1 Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
03/25/2010WO2010031828A1 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer
03/25/2010WO2010031783A1 Mutant pestivirus with mutations in core gene and ns3 region
03/25/2010WO2010031519A1 Transcutaneous compositions for specific immuno-modulatory treatment
03/25/2010WO2010031171A1 Iap bir domain binding compounds
03/25/2010WO2010031113A1 Viral polypeptides and methods
03/25/2010WO2010016760A3 Immunogenic composition for the treatment of e. faecium infection
03/25/2010WO2010014854A3 Antibodies that neutralize botulinum neurotoxins
03/25/2010WO2010014595A3 Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
03/25/2010WO2010009277A9 Immunogenic amphipathic peptide compositions
03/25/2010WO2010006315A3 Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents
03/25/2010WO2009156405A8 Novel immunoadjuvant flagellin-based compounds and use thereof
03/25/2010WO2009155489A3 Compositions and methods for treating influenza
03/25/2010WO2009149397A3 Respiratory syncytial virus renders dendritic cells tolerogenic
03/25/2010WO2009148488A3 Use of oncolytic herpes viruses for killing cancer stem cells
03/25/2010WO2009141729A3 Anti-tumoral cells
03/25/2010WO2009137577A3 Leishmania vaccine using sand fly salivary immunogen
03/25/2010WO2009130588A3 Codon-optimzed hepatitis b virus core antigen (hbcag)
1 ... 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 ... 1823